Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL )

2.920 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 519
Open 2.920
Bid (Size) 2.940 (2)
Ask (Size) 3.670 (6)
Prev. Close 2.920
Today's Range 2.920 - 2.920
52wk Range 2.470 - 9.240
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024
VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire

Performance

YTD
-15.85%
-15.85%
1 Month
-30.48%
-30.48%
3 Month
-16.21%
-16.21%
6 Month
-5.65%
-5.65%
1 Year
-50.00%
-50.00%

More News

Read More
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience: Q4 Earnings Insights
Via Benzinga
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
Via Benzinga
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
Via InvestorPlace
Why Is Branchout Food (BOF) Stock Down 39% Today?
Via InvestorPlace
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
From Vigil Neuroscience, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
Via InvestorPlace
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
Vigil Neuroscience to Present in Upcoming June Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
Via InvestorPlace
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
Via InvestorPlace
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.